Omega Ophthalmics is developing the Gemini Refractive Capsule, designed to create a biologically integrated platform for intraocular lens implantation that preserves the capsular bag and aims to improve long-term refractive stability. The company positions the technology to enable future lens exchange and accommodate next-generation ophthalmic innovations. Omega recently scheduled an FDA pre-submission meeting to align its regulatory pathway and clinical plans with the Agency and is preparing for U.S. clinical studies. Financially, it has secured $7 million in Series A financing to support product development, IP, regulatory activities, manufacturing scale-up, and clinical planning. The company presented its vision and clinical development strategy at the Octane Ophthalmology Tech Forum as it advances toward commercialization.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2026